KPV Peptide: Structure, PepT1 Transport and Cellular Signalling

KPV is three residues, Lys-Pro-Val, clipped off the C-terminus of alpha-melanocyte-stimulating hormone at positions 11 to 13. About as small as a peptide can get and still do something specific. What makes its literature worth reading is mechanism: how it crosses the membrane, what it does to NF-kappaB once it is inside, and whether the melanocortin-1 receptor is involved at all. On that last point the answer looks like no, or at least not necessarily, which is odd for a melanocortin fragment.

A fragment that kept the message

Alpha-MSH is a 13 residue melanocortin. When researchers cut it down looking for the minimal active sequence, the C-terminal tripeptide kept showing activity in assays where the parent peptide worked, and KPV became known as the smallest fragment reported to retain that activity [3]. Three residues is small enough that the usual receptor binding logic starts to look shaky, and that tension runs through the whole literature on this molecule.

Elliott and colleagues went after the question directly in human keratinocytes [3]. Alpha-MSH signals through MC-1R by raising cyclic AMP in many cell types, so the straightforward prediction was that KPV would do the same. It did not. Neither HaCaT cells nor normal human keratinocytes showed any cyclic AMP elevation in response to alpha-MSH, KPV, KP-D-V or ACTH peptides. What they did show was rapid intracellular calcium flux in response to KPV across a remarkably wide concentration range, from 10 to the minus 15 up to 10 to the minus 7 molar, and only when the cyclic AMP pathway was inhibited by an adenosine agonist. In Chinese hamster ovary cells stably transfected with MC-1R, both alpha-MSH and the KPV peptides raised intracellular calcium. So there is a receptor interaction available, but the second messenger is not the one textbook melanocortin signalling predicts.

Getting into the cell: PepT1

Dalmasso and colleagues supplied the cleanest mechanistic piece [2]. They stimulated human intestinal epithelial lines, Caco2-BBE and HT29-Cl.19A, plus Jurkat T cells with pro-inflammatory cytokines, with and without KPV, and read out NF-kappaB activity by luciferase reporter alongside Western blot, real-time RT-PCR and ELISA. Nanomolar concentrations were enough to suppress NF-kappaB and MAP kinase activation and reduce cytokine secretion.

Then they asked how the tripeptide got in. Using unlabelled KPV as a competitor against a radiolabelled PepT1 substrate, and tritiated KPV to measure uptake kinetics directly, they showed transport via PepT1, the di- and tripeptide transporter expressed in epithelial and immune cells. That detail explains a lot. Why would a three residue peptide need its own cell surface receptor when a general oligopeptide transporter will carry it in? Once inside it can hit intracellular signalling nodes directly. It also puts a hard limit on analogue design, since anything longer than three residues loses PepT1 as a route.

Receptor independence in knockout animals

Kannengiesser and colleagues ran KPV through two murine colitis models, dextran sodium sulfate induced and CD45RB-high transfer [4]. Colon histology and myeloperoxidase activity both fell. The third arm is the one that matters here: mice carrying a nonfunctional melanocortin-1 receptor responded too, so the authors concluded the effects were at least partly independent of MC1R. Line that up with the keratinocyte cyclic AMP result and the PepT1 transport data and the picture holds together. The action looks intracellular, not classical receptor engagement.

Antimicrobial behaviour and the dimer

Cutuli and colleagues tested alpha-MSH and KPV against two organisms [1]. The peptides inhibited S. aureus colony formation and reversed urokinase driven enhancement of it, and affected C. albicans viability and germ tube formation across a broad concentration range. Their proposed mechanism was an increase in cellular cyclic AMP in the target organism, which was supported by the fact that an adenylyl cyclase inhibitor interfered with the effect. Human neutrophil killing of both organisms was not reduced by the peptides and was if anything enhanced.

That line of work led somewhere structurally interesting. Catania’s group joined two KPV units with a Cys-Cys linker to make the dimer [Ac-CKPV]2, which was active against azole-resistant Candida species, and then solved its solution structure by proton NMR with restrained mechanics and dynamics calculations [5]. The peptide adopted an extended backbone with a beta-turn-like element. For a molecule this small, knowing there is a defined conformation at all is informative, since tripeptides are usually assumed to be floppy. Our notes on LL-37 and antimicrobial peptide research cover a very different structural approach to the same assay problem.

Formulation work

Because KPV is water soluble, small and rapidly absorbed, most of the delivery literature is about keeping it where you want it rather than getting it in. Xiao and colleagues loaded KPV into hyaluronic acid functionalized polymeric nanoparticles with a mean size near 272 nm and a slightly negative zeta potential of about minus 5.3 mV, then encapsulated those in a chitosan and alginate hydrogel [6]. The nanoparticles were taken up by colonic epithelial cells and macrophages, appeared non-toxic to intestinal cells, and the hydrogel system outperformed nanoparticles alone in a mouse model, with lower TNF-alpha. It is a reasonable illustration of how much of a small peptide’s measured activity depends on the carrier around it.

Working with the material

Three residues means synthesis is trivial and characterization should be straightforward, which creates its own trap: people assume a tripeptide needs less verification than a long one. It does not. Reversed phase HPLC on such a short, polar sequence needs an appropriate column and gradient, since KPV has little hydrophobic character to retain it, and a poorly chosen method can push peptide and impurities through together near the void volume. Mass spectrometry confirms the mass, but at 342 daltons the mass is close enough to common adducts and matrix peaks that identity should rest on a fragment spectrum, not a single intact value. Chromatographic content assignment plus orthogonal identity testing is the standard expected of synthetic peptide reference materials, and it applies to short sequences too [7]. Check the certificate of analysis and what the third party testing actually covered.

Frequently asked questions

What is KPV made of?

Lysine, proline and valine, in that order, corresponding to residues 11 to 13 of alpha-MSH [1].

Does KPV act through the melanocortin-1 receptor?

Not exclusively. It raised intracellular calcium in MC-1R transfected cells [3], but it also worked in mice with a nonfunctional MC1R [4], and it is transported into cells by PepT1 [2].

Why is PepT1 relevant to a tripeptide?

PepT1 carries di- and tripeptides across epithelial membranes. Being exactly three residues long is what makes KPV a substrate, which gives it an intracellular route no larger peptide fragment of alpha-MSH has [2].

References

1. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000. PMID 10670585
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177
3. Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004. PMID 15102092
4. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346
5. Catania A, Grieco P, Randazzo A, et al. Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2. J Pept Res. 2005. PMID 15946192
6. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017. PMID 28143741
7. McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023. PMID 36949371